92 results about "Ketamine" patented technology

The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.

A pharmaceutical composition and use thereof in preparing a drug for preventing and / or treating major depressive disorder. The pharmaceutical composition comprises: ketamine, and a pharmaceutically acceptable idazoxan salt or a derivative thereof. The idazoxan hydrochloride in the pharmaceutical composition can effectively promote the antidepressant effect of ketamine, and significantly reduce the dose of ketamine required to exert the antidepressant effect, thereby prolonging the duration of the antidepressant effect.

The invention discloses a ketamine derivative and application thereof in treatment of mental diseases, and belongs to the technical field of medicines. The compound or the pharmaceutical composition thereof provided by the invention can obviously improve the expression quantity of nerve cells BDNF, promote the growth of neurite, inhibit NMDA receptor signals and treat acute and chronic depression, has improved oral bioavailability compared with ketamine, and can be used for treating mental diseases such as depression.

A dry powder inhalable pharmaceutical composition comprising ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression by administration via pulmonary route. The composition is especially useful for the treatment of treatment-resistant or treatment-refractory depression.

The invention provides a sterile, injectable pharmaceutical composition which includes a therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof, a nitrite scavenger, a tonicity agent, and water, wherein the composition contains less than about 300 ppb of an N-nitrosoketamine impurity. The invention also provides a pharmaceutical product which includes a container and the composition of the invention aseptically sealed therein. The invention further provides a process for preparing the composition and product of the invention.

To provide arylcyclohexylamine compounds and their use in the treatment of psychiatric disorders.SOLUTION: There are provided arylcyclohexylamine compounds and compositions of a single enantiomer or enantiomerically enriched mixtures of arylcyclohexylamine having significantly higher oral bioavailability, higher antidepressant potency, and / or greater therapeutic index between antidepressant effects and side effects, compared to ketamine.SELECTED DRAWING: None

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

The present disclosure provides a method for treating or ameliorating depressive symptoms in a subject, the method comprising administering to the subject a therapeutically effective amount of a composition comprising R(-)-ketamine or a pharmaceutically acceptable salt thereof.

The invention discloses an aptamer sensor for detecting a novel psychoactive substance ketamine and application of the aptamer sensor. Belongs to the technical field of poison detection. The aptamer sensor for detecting the novel psychoactive substance ketamine is successfully established by taking a two-dimensional nano material as a fluorescence quencher and a carrier, chemically coupling the two-dimensional nano material with a double-chain nucleic acid aptamer through a liquid-phase amidation reaction and carrying out surface passivation treatment, so that the chemical coupling efficiency is greatly improved; and the stability and the sensitivity of the sensor are enhanced. In addition, when the sensor is introduced into complex biological matrixes such as blood, urine and saliva, the system does not display non-specific signals, and compared with a physical adsorption system, the KET in complex biological fluid can be reliably detected, and a new thought and method are provided for reliable detection of other novel psychoactive substances.

The present invention relates to administration regimes of 2-(2-Chlorphenyl)-2- (methylamino) cyclohexan-1-one, also known as ketamine, or derivatives thereof, for the use in treating depression, in particular treatment resistant depression.

The present invention provides (S)- or (R)-ketamine prodrugs and compositions thereof for the treatment or prevention of depression and pain. [Solution] A compound of formula (1) or a pharmaceutically acceptable salt thereof (wherein R1 is hydrogen or alkyl, and R2 is a group of formula (6)) is provided. JPEG2026123016000361.jpg3980 JPEG2026123016000362.jpg2379

Provided herein are ketamine formulations for subcutaneous injection, in particular subcutaneous formulations of ketamine useful for the treatment of various diseases and disorders. The subcutaneous ketamine preparation provided by the invention reduces stimulation and pain of an injection site.

Methods and compositions that treat Alzheimer's disease and other neurodegenerative diseases and / or to ameliorate or improve symptoms associated with Alzheimer's disease. In some aspects, the compositions and methods use a serotonin 4 receptor (5-hydroxytryptamine (serotonin) receptor 4, or 5-HT4R) agonist in combination with: (R,S)-ketamine, a (R,S)-ketamine analog, or a pharmaceutically acceptable salt, derivative, or metabolite thereof; an antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor (NMDAR); or an agonist of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (AMPAR).

The invention relates to the technical field of drug detection, in particular to an environment drug detection and collection reagent and a use method thereof.The environment drug detection and collection reagent comprises 0.05%-5% of a preservative, 0.5%-10% of a scale inhibitor, 0.1%-5% of a surfactant and a pH regulator; the pH value of the drug detection and collection reagent in the environment is 6.5-8.5; the detection and collection reagent for the drugs in the environment is wide in application range, and can be suitable for rapid collection and detection of the drugs such as morphine, methamphetamine, ketamine, cocaine, cannabis sativa, ecaloin, etomidate and dextromethorphan. The drug detection and collection reagent can effectively reduce the detection threshold value of a high-sensitivity detection plate, further improves the sensitivity of drug detection and analysis, and is suitable for further popularization and application.

Provided herein are subcutaneous formulations of ketamine that are useful for treating a variety of disease and disorders. The subcutaneous ketamine formulations provided herein reduce injection site irritation and pain.

The invention belongs to the technical field of medicines, and particularly relates to an esketamine and mirtazapine synergistic antidepressant pharmaceutical composition and application thereof. The antidepressant pharmaceutical composition comprises the following active components: esketamine and mirtazapine, the esketamine is an N-methyl-D-aspartic acid receptor antagonist, and the mirtazapine is an adrenergic alpha2-AR antagonist. According to the anti-depression pharmaceutical composition containing esketamine and mirtazapine, through the synergistic effect of esketamine and mirtazapine, the effects of reducing dosage, prolonging aging and reducing adverse reactions are achieved, and major depressive disorder is safely and effectively prevented and treated.

The invention provides the composite injection containing ketamine and citalopram, and when the composite injection is used for treating depressive disorder, the composite injection takes effect more quickly and responds more accurately, the effect delay period can be further shortened, and the anti-depression curative effect can be further improved. And the medicine is more convenient to take, and the medication compliance is greatly improved.

The invention relates to fast-acting, multi-layered, orally disintegrating, and film-shaped pharmaceutical formulations containing anesthetic drugs (midazolam, ketamine, atropine, or a combination thereof) used to provide sedation in children prior to surgical operations or interventions, and the production method of these formulations.

The application belongs to the technical field of medicine, and discloses application of oxeladin in preparation of a medicine for preventing or treating perioperative hypothermia. The dose of the medicine ranges from 1 to 3 mg. The medicine is applied to perioperative hypothermia caused by general anesthesia. The general anesthesia includes sevoflurane and esketamine. The medicine further comprises a pharmaceutically acceptable carrier and / or excipient. It is found in the previous application that the incidence of hypothermia and chills after general anesthesia is significantly reduced in the oxeladin administration group compared with the blank control group, and the further verification is carried out through animal experiments. The achievement of the application provides an effective prevention and treatment scheme for improving perioperative hypothermia and chills in clinic.

The invention relates to pharmaceutical compositions comprising ketamine or pharmaceutically acceptable salt thereof for nasal administration, and methods for using such compositions.

The invention relates to the technical field of biological analysis and detection, in particular to a cucurbituril derivative for drug detection, a preparation method and application of the cucurbituril derivative, a detection probe containing the cucurbituril derivative, a drug for treating acute poisoning of drugs and a drug detection method. On the basis of retaining the original supramolecular recognition characteristic of cucurbituril, the derivative introduces an o-cyanobenzaldehyde (CNBA) functional group; the obtained compound can realize high-efficiency covalent capture on common drugs and metabolites thereof (such as primary amine groups in molecules of methylamphetamine and metabolites thereof, 3, 4-methylenedioxy methylamphetamine, ketamine and metabolites thereof, fluazinone and metabolites thereof, phencyclohexylpiperidine, cathinone and the like); therefore, rapid and high-sensitivity visual detection of the target object is realized, and the method can be used for antagonistic treatment of acute poisoning caused by related drugs and metabolites.

The present invention features methods and compositions for the treatment of an emotional disorder in a subject by administering ketamine, norketamine, 6-hydroxynorketamine, or a pharmaceutically acceptable salt thereof, and cannabis or a cannabinoid in an amount that is sufficient to treat the emotional disorder.

The present invention relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day.

The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder.

The invention belongs to the technical field of medicines, and particularly relates to an antidepressant pharmaceutical composition and application thereof. The antidepressant pharmaceutical composition is prepared from the following active ingredients: esketamine and mianserin, the esketamine is an N-methyl-D-aspartic acid receptor antagonist, and the mianserin is a central presynaptic adrenergic alpha2-AR antagonist. The invention further discloses a preparation method of the pharmaceutical composition. Escketamine and mianserin play an anti-depression role in different ways, and after combined use, not only is the drug dosage of the escketamine reduced, but also the anti-depression action time of the escketamine is prolonged, and a synergistic amplification effect is generated.

The disclosure provides a method of treating or ameliorating depressive symptoms of a subject, comprising administering a therapeutically effective amount of a composition comprising R(−)-ketamine, or a pharmaceutically acceptable salt thereof, to the subject.